1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
625AE5E4DCCC0BCFA0025854B00206EF8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-thought-leader-management-excellence-structure-coordination-communication-high-performing-external-stakeholder-engagement-system?opendocument
18
19opendocument
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Thought Leader Services

Thought-leader Management Excellence: Structure, Coordination and Communication for a High-performing External Stakeholder Engagement System

ID: 5609


Features:

9 Info Graphics

13 Data Graphics

85+ Metrics

6 Narratives


Pages/Slides: 29


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Thought-leader Management Excellence: Structure, Coordination and Communication for a High-performing External Stakeholder Engagement System”

STUDY OVERVIEW

In today’s competitive and restricted marketplace, thought leader management and engagement is a critical component of success – from the early development stage through post market entry.

Forward-thinking companies have built highly coordinated, well-administered, and optimally structured thought-leader management systems to nurture the right relationships with the right thought leaders at the right times.

Best Practices, LLC undertook this benchmarking research to help Medical Affairs leaders develop optimal thought-leader management systems across key program dimensions. This research enables Medical Affairs leaders to improve performance and make better decisions by helping them assess the impact of the structure, administration, internal communication and coordination of their thought-leader management systems.

KEY TOPICS
  • Impact of Organizational Structure on Thought-leader Management System Effectiveness
  • Administering Strategic Thought Leader Management & Engagement
  • Effective Coordination & Communication for Strategic Thought-leader Management and Engagement

KEY METRICS
  • What is the optimal organizational structure for Thought-leader management and engagement?
  • How much do you feel your organization values the day-to-day Thought-leader management and engagement work done by your staff?
  • Does your company’s strategy for Thought-leader management and engagement have executive sponsorship?
  • Does your organization have separate roles for strategic Thought-leader management and engagement and Thought-leader relationship responsibilities?
  • How many non-field based FTEs are involved in your strategic Thought-leader management and engagement system?
  • In your experience, what are the most effective ways to coordinate (strategic) Thought-leader (management and engagement) activities across different functions and/or groups?
  • Please indicate which communication channels your organization uses to allow those involved with strategic Thought-leader management and engagement to share learnings/best practices with each other

SAMPLE KEY FINDINGS
  • Structure: Decentralized Thought Leader Management structures are the most frequent (49%), but are often rife with poor communication and coordination. Most experts identify Hybrid or Centralized structures as optimal (97% combined).
  • Communication: Frequent and standardized direct communication is essential for success, while over-reliance on databases fosters internal misalignment.

METHODOLOGY

Best Practices, LLC engaged 35 biopharma leaders at 31 companies through a benchmarking survey instrument, interviews and a roundtable discussion in this research.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Consulting; Biotech; Medical Device; Manufacturing; Health Care; Clinical Research; Laboratories


Companies Profiled:
Adamas Pharmaceuticals; Alkermes; Alligent Group; Amgen; Antiva Bioscience; Asofarma; Beckman Coulter; Biogen; Boston Scientific; Cipla; Eisai; EMD Serono; Fidia; Fresenius Medical Care; Galderma; IQVIA; LEO Pharma; Melinta Therapeutics; Inc; Merck; Merck Healthcare KGaA; Mylan; Novartis; Nutricia; Pfizer; Rakuten Medical; Sanofi; Santen; Servier; Shire; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.